» Articles » PMID: 10657410

Effect of Hypervolemic Therapy on Cerebral Blood Flow After Subarachnoid Hemorrhage : a Randomized Controlled Trial

Overview
Journal Stroke
Date 2000 Feb 5
PMID 10657410
Citations 119
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Cerebral blood flow (CBF) is reduced after subarachnoid hemorrhage (SAH), and symptomatic vasospasm is a major cause of morbidity and mortality. Volume expansion has been reported to increase CBF after SAH, but CBF values in hypervolemic (HV) and normovolemic (NV) subjects have never been directly compared.

Methods: On the day after aneurysm clipping, we randomly assigned 82 patients to receive HV or NV fluid management until SAH day 14. In addition to 80 mL/h of isotonic crystalloid, 250 mL of 5% albumin solution was given every 2 hours to maintain normal (NV group, n=41) or elevated (HV group, n=41) cardiac filling pressures. CBF ((133)xenon clearance) was measured before randomization and approximately every 3 days thereafter (mean, 4.5 studies per patient).

Results: HV patients received significantly more fluid and had higher pulmonary artery diastolic and central venous pressures than NV patients, but there was no effect on net fluid balance or on blood volume measured on the third postoperative day. There was no difference in mean global CBF during the treatment period between HV and NV patients (P=0.55, random-effects model). Symptomatic vasospasm occurred in 20% of patients in each group and was associated with reduced minimum regional CBF values (P=0.04). However, there was also no difference in minimum regional CBF between the 2 treatment groups.

Conclusions: HV therapy resulted in increased cardiac filling pressures and fluid intake but did not increase CBF or blood volume compared with NV therapy. Although careful fluid management to avoid hypovolemia may reduce the risk of delayed cerebral ischemia after SAH, prophylactic HV therapy is unlikely to confer an additional benefit.

Citing Articles

Effectiveness of human albumin for clinical outcome in aneurysmal subarachnoid hemorrhages: a protocol for randomized controlled (HASH) trial.

Ali A, Khan M, Shaikh N, Mohamad A, Al-Maadhadi M, Shah N Trials. 2025; 26(1):53.

PMID: 39953562 PMC: 11827198. DOI: 10.1186/s13063-025-08762-5.


Endovascular therapy for cerebral vasospasm after aneurysmal subarachnoid hemorrhage: Single-center experience in a high-volume neurovascular unit.

Albrecht C, Liang R, Trost D, Hostettler I, Renz M, Meyer B Brain Spine. 2024; 4:104133.

PMID: 39582526 PMC: 11582754. DOI: 10.1016/j.bas.2024.104133.


Prevention of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage-Summary of Existing Clinical Evidence.

Miller M, Thappa P, Bhagat H, Veldeman M, Rahmani R Transl Stroke Res. 2024; 16(1):2-17.

PMID: 39212835 DOI: 10.1007/s12975-024-01292-3.


CT perfusion-guided administration of IV milrinone is associated with a reduction in delayed cerebral infarction after subarachnoid hemorrhage.

Szabo V, Baccialone S, Kucharczak F, Dargazanli C, Garnier O, Pavillard F Sci Rep. 2024; 14(1):14856.

PMID: 38937568 PMC: 11211472. DOI: 10.1038/s41598-024-65706-w.


Effects of Dl-3-n-butylphthalide on neurological function, hemodynamics and Hcy concentration in cerebral hemorrhage: a systematic review and meta-analysis.

Ma Y, Guo C, Wang Y, Liu X Front Pharmacol. 2024; 15:1360932.

PMID: 38881880 PMC: 11177091. DOI: 10.3389/fphar.2024.1360932.